Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ASMB
- Price
- 10.20
- Stock movement up
- +1.12 (12.33%)
- Company name
- Assembly Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 64.83M
- Ent value
- 110.64M
- Price/Sales
- 2.29
- Price/Book
- 2.49
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -22.47%
- 1 year return
- -32.27%
- 3 year return
- -28.03%
- 5 year return
- -44.58%
- 10 year return
- -25.83%
Last updated: 2025-04-14
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ASMB does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | 2.83 |
| Price to FCF | 2.84 |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.29 |
| Price to Book | 2.49 |
| EV to Sales | 3.91 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 6.36M |
| EPS (TTM) | -6.42 |
| FCF per share (TTM) | 3.60 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 28.33M |
| Gross profit (TTM) | 28.18M |
| Operating income (TTM) | -46.44M |
| Net income (TTM) | -40.80M |
| EPS (TTM) | -6.42 |
| EPS (1y forward) | -8.03 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 99.48% |
| Operating margin (TTM) | -163.94% |
| Profit margin (TTM) | -144.05% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 28.45M |
| Net receivables | 0.00 |
| Total current assets | 98.21M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 1.74M |
| Total assets | 100.26M |
| Accounts payable | 1.33M |
| Short/Current long term debt | 1.44M |
| Total current liabilities | 41.63M |
| Total liabilities | 74.26M |
| Shareholder's equity | 26.00M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 22.94M |
| Capital expenditures (TTM) | 99.00K |
| Free cash flow (TTM) | 22.84M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -156.92% |
| Return on Assets | -40.70% |
| Return on Invested Capital | -149.29% |
| Cash Return on Invested Capital | 83.56% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 9.37 |
| Daily high | 10.36 |
| Daily low | 9.37 |
| Daily Volume | 20K |
| All-time high | 1215.00 |
| 1y analyst estimate | 35.50 |
| Beta | 0.59 |
| EPS (TTM) | -6.42 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 May 2025 |
Downside potential
Loading...
Downside potential data
| ASMB | S&P500 | |
| Current price drop from All-time high | -99.16% | -12.04% |
| Highest price drop | -99.36% | -56.47% |
| Date of highest drop | 22 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -82.34% | -11.07% |
| Avg time to new high | 106 days | 12 days |
| Max time to new high | 3505 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
64.83M
Marketcap category
Small-cap
Description
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Employees
65
Website
Investor relations
-
SEC filings
CEO
John G. McHutchison
Country
USA
City
South San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page